What the Trials Showed Tirzepatides efficacy is established across two landmark NEJM trials: SURMOUNT-1 (obesity) and SURPASS-2 (a head-to-head against semaglutide in type 2 diabetes)
Eli Lilly showed a similar pattern
That part doesnt change based on which peptide you choose.If you want that kind of structured approach, physician-led evaluation, baseline and ongoing IGF-1 monitoring, honest sourcing, and a protocol matched to your goal rather than a default, thats the model TRTMD is built around
For people looking to take advantage of the health benefits of GHK-Cu, it is often provided through an injection
Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z